Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Leukemia 3Neoplasm, Residual 2Down Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

fludarabine 4fludarabine phosphate 3asciminib 3venetoclax 2gilteritinib 2Whole-Body Irradiation 2Tacrolimus 2Idarubicin 2Cytarabine 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2ponatinib 1nilotinib 1enasidenib 1blinatumomab 1aldesleukin 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Methotrexate 1Mesna 1Melphalan 1Interleukin-2 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × blinatumomab × 90 days × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡